LOS ANGELES, Jan 8 (Reuters) - Incyte Corp (INCY.O: Quote, Profile, Research) shares rose 20 percent on Tuesday after the biotechnology company reported encouraging data from early-stage studies of its experimental drugs for rheumatoid arthritis and diabetes.
